Biotech Values

[ghmm]

HALO:

I don't think I would go that far. My question about management relate more to other issues. The CRL was not exactly hidden from anyone and those surprised by it weren't following the story. The surprise was the magnitude of the impact (to at least sub-q cinryze).

The next days/week may be ugly for the stock no doubt and everyone will come out of the woodwork saying why they new and rip the stock/management/etc. It remains to be seen what will happen longer term if Herceptin sub-q and Mabthera sub-q get the EU nod then the prices of tonight and the coming days may look quite cheap.

http://www.morningstar.com/earnings/PrintTranscript.aspx?id=40764170
(from the Q1 call)

Moving on to our other late stage partner programs I want to comment on the recent update with our partner Baxter HyQ Biologics License application. FDA recently requested additional information regarding the investigational therapy HyQ in order to complete its review of the application to treat patients with primary immune deficiency. As a reminder, HyQ is a product that is co-administered and include Baxter's Immune Globulin and Halozyme's Recombinant Human Hyaluronidase for which for which BLA was submitted to FDA for the treatment of primary immunodeficiency. We continue to work closely with Baxter to clarify a FDA's questions, develop an action plan and generate data to satisfy their request. FDA indicated in the request that additional information could be satisfied through preclinical or clinical studies, but clarifying discussions will be required before we can provide a more definitive timeline. However, currently we anticipate the potential approval timeline to extend beyond 2012.